Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06636981RecruitingPhase 2
Combination therapy for advanced triple negative breast cancer
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06657157Recruiting
Nerve side effects study for new bladder cancer treatment
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
Augsburg, BavariaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06796907RecruitingPhase 1/Phase 2
Mocertatug rezetecan with other drugs for advanced solid tumors
This trial tests a new drug, mocertatug rezetecan, combined with other anti-cancer therapies for people with advanced solid tumors like endometrial or ovarian cancer. It aims to see if the combination is safe and effective.
La Jolla, CaliforniaAges 18 years+ - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Sarasota, FloridaAges 18 years+ - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06738966RecruitingPhase 1
BL0175 for advanced HR-positive breast or gynecologic cancer
This trial tests a new drug called BL0175 for women with certain types of advanced breast, ovarian, or endometrial cancer that have stopped responding to hormone therapy. The goal is to see if the drug can help shrink tumors or slow down the cancer.
Changchun, JilinAges 18 years+ - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06759649RecruitingPhase 1
Study of COM503 for advanced solid tumors
This trial tests a new drug called COM503 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. It aims to see if the drug is safe and how well it works.
New Haven, ConnecticutAges 18 years+ - NCT06767527RecruitingPhase 3
AK112 plus chemo for first-line triple-negative breast cancer
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
BeijingAges 18–75 - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT06797297RecruitingPhase 2
Study of IBI363 vs pembrolizumab for advanced mucosal or acral melanoma
This trial tests a new drug, IBI363, compared to the standard drug pembrolizumab (Keytruda) for people with advanced mucosal or acral melanoma who have not had treatment before. It aims to see if IBI363 works better or as well as the usual treatment.
Hefei, AnhuiAges 18 years+ - NCT06823427RecruitingPhase 2
9MW2821 with or without immunotherapy for advanced urothelial cancer
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
Changsha, HunanAges 18–80 - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT06831136RecruitingPhase 2
Endoscopic ultrasound ablation plus immunotherapy for pancreatic cancer
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
Houston, TexasAges 18 years+ - NCT06833229Recruiting
Can a PET scan predict if immunotherapy is working?
This study uses a special PET-CT scan early in your treatment to see if immunotherapy (with or without chemotherapy) is working against your advanced lung cancer. The goal is to find out faster if the treatment is helping.
NiceAges 18 years+ - NCT06838273RecruitingPhase 3
Testing a new drug combo for EGFR-mutated lung cancer
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06859684RecruitingPhase 2
Triple therapy for advanced bile duct cancer of the liver
This trial tests a combination of three treatments for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The treatments include a chemotherapy infusion directly into the liver artery (HAIC), an immunotherapy drug (durvalumab), and a targeted therapy pill (lenvatinib). It aims to see if this triple therapy can shrink or control the cancer better than standard treatments.
Chengdu, SichuanAges 18–75 - NCT06873269Recruiting
Holmium-166 radiation therapy for liver cancer
This trial tests a radiation treatment for liver cancer that cannot be removed with surgery or ablation. Tiny beads containing Holmium-166 are injected into the liver's blood supply to target the tumor directly.
BrusselsAges 18 years+ - NCT06884618RecruitingPhase 1
Study of RO7673396 for advanced solid tumors with RAS mutations
This trial tests a new drug, RO7673396, for people with advanced solid tumors that have a RAS mutation. The goal is to see if the drug is safe and works against the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06896162Recruiting
Genetic test to guide first or second treatment for advanced cancer
This study looks at whether using a detailed genetic test of your tumor can help pick the best first or second treatment for advanced lung, colon, breast, or bladder cancer. The goal is to see if this personalized approach helps people live longer.
Chapel Hill, North CarolinaAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.